Annexon (ANNX) Accumulated Expenses (2019 - 2026)
Annexon (ANNX) posted quarterly Accumulated Expenses of $2.3 million for Q1 2026, down 89.0% year-over-year from $20.5 million in Q1 2025, and down 90.91% quarter-over-quarter from $24.8 million in Q4 2025.
Annexon (ANNX) Accumulated Expenses (2019 - 2026) Analysis & Trends
Annexon's Accumulated Expenses history runs 8 years deep, the most recent figure standing at $2.3 million for Q1 2026.
- In Q1 2026, Accumulated Expenses fell 89.0% year-over-year to $2.3 million; the TTM figure through Mar 2026 stood at $2.3 million (down 89.0% YoY), while the FY2025 annual figure was $24.8 million, up 41.11% from the prior year.
- Accumulated Expenses for Q1 2026 stood at $2.3 million, down from $24.8 million in the prior quarter.
- The five-year high for Accumulated Expenses was $26.4 million in Q2 2025, with the low at $1.4 million in Q1 2022.
- The 5-year median for Accumulated Expenses is $8.1 million (2022), against an average of $10.4 million.
- The sharpest annual moves came in 2025 and 2026: Accumulated Expenses surged 1147.35% in 2025, then tumbled 89.0% in 2026.
- Annexon's Accumulated Expenses stood at $5.3 million in 2022, then rose by 5.81% to $5.6 million in 2023, then surged by 213.32% to $17.6 million in 2024, then surged by 41.11% to $24.8 million in 2025, then tumbled by 90.91% to $2.3 million in 2026.
- Business Quant data shows ANNX's Accumulated Expenses at $2.3 million in Q1 2026, $24.8 million in Q4 2025, and $22.5 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Annexon | 1.00 Bn | 1.00 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 19.63 Mn |
| Mar 31, 2026 | 2.25 Mn |
| Dec 31, 2025 | 24.79 Mn |
| Sep 30, 2025 | 22.54 Mn |
| Jun 30, 2025 | 26.41 Mn |
| Mar 31, 2025 | 20.49 Mn |
| Dec 31, 2024 | 17.57 Mn |
| Sep 30, 2024 | 10.86 Mn |
| Jun 30, 2024 | 10.66 Mn |
| Mar 31, 2024 | 1.64 Mn |
| Dec 31, 2023 | 5.61 Mn |
| Sep 30, 2023 | 4.86 Mn |
| Jun 30, 2023 | 8.95 Mn |
| Mar 31, 2023 | 2.05 Mn |
| Dec 31, 2022 | 5.30 Mn |
| Sep 30, 2022 | 3.79 Mn |
| Jun 30, 2022 | 8.06 Mn |
| Mar 31, 2022 | 1.38 Mn |
| Dec 31, 2021 | 9.25 Mn |
| Sep 30, 2021 | 7.06 Mn |